Biopharmaceutical company Lysogene (Paris:LYS) on Friday revealed that its cash and cash equivalents amounted to EUR26.5m as of 31 December 2019.

This marks a decline when compared with cash and cash equivalents of EUR29.1m as of 30 September 2019.

The 2019 cash and cash equivalents include the payments from Sarepta Therapeutics Inc related to the milestone payment and development cost reimbursement triggered by dosage of the first patient in AAVance, the Phase 2/3 clinical trial of LYS-SAF302 in MPS IIIA. The license and collaboration agreement with Sarepta Therapeutics Inc generated in 2019 revenues of EUR12.0m.

At the end of 2019, the cash position is in line with the company's expectations and allows to serenely advance the development programme of the 16th patient under its Phase 2/3 clinical trial of LYS-SAF302 in MPS IIIA, said Karen Aiach, founder and CEO.